Tempus AI, Inc. (TEM) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Tempus AI, Inc. is a healthcare technology company focused on applying artificial intelligence and machine learning to improve patient care through genomic testing, data licensing, and clinical trial matching. The quarter was defined by significant strategic expansion, most notably the acquisition of Ambry Genetics Corporation.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Net Revenue | $255.7 million | $145.8 million |
| Net Loss | $(68.0) million | $(64.7) million |
| Adjusted EBITDA | $(16.2) million | $(43.9) million |
| Cash and Cash Equivalents | $151.6 million | $79.9 million |
| Total Debt (Long-term + Revolver) | $567.1 million | $267.2 million |
| Operating Cash Flow | $(105.6) million | $(101.4) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 75% year-over-year, driven by an 89% increase in Genomics revenue and a 43% increase in Data and Services revenue.
- Acquisition Impact: The acquisition of Ambry Genetics (closed Feb 3, 2025) contributed $63.5 million to Genomics revenue and significantly increased test volume (from ~62,700 to ~153,000 tests).
- Expense Expansion: Selling, General, and Administrative (SG&A) expenses surged 94% to $154.6 million, primarily due to personnel costs, stock-based compensation, and amortization of intangibles from the Ambry acquisition.
- Debt Financing: To fund the Ambry acquisition, the company secured an additional $200 million term loan and drew $100 million on a new revolving credit facility, increasing total debt obligations significantly.
- Tax Benefit: A discrete income tax benefit of $46.2 million was recorded due to the release of a valuation allowance related to deferred tax liabilities from the Ambry acquisition.
Guidance, Outlook, and Risks
- Strategic Outlook: Management emphasizes the integration of Ambry to expand into hereditary cancer screening and new disease categories (pediatrics, cardiology). The company continues to invest heavily in R&D and technology infrastructure.
- Subsequent Events: In April 2025, Tempus entered into a $200 million data licensing agreement with Pathos AI and a $35 million fee agreement with AstraZeneca for the development of a foundational oncology AI model.
- Liquidity: Management believes current cash, marketable securities, and anticipated cash flows are sufficient to fund operations for at least 12 months.
- Risks: Key risks include the ability to secure reimbursement from payers (Medicare/Medicaid), integration risks from recent acquisitions, and ongoing legal proceedings, including a patent infringement lawsuit filed by Guardant Health.
Investor Verification Checklist
- Reimbursement Rates: Verify the sustainability of the increased average revenue per Oncology test ($1,590 vs $1,450 in Q1 2024) and payer coverage trends.
- Debt Covenants: Review the new credit agreement covenants, specifically the requirement to maintain minimum consolidated revenues of $1.0 billion (trailing twelve months) and minimum liquidity of $25 million.
- Integration Costs: Assess the timeline for realizing synergies from the Ambry acquisition against the immediate increase in amortization and personnel costs.
- Legal Exposure: Monitor the status of the Guardant Health patent litigation and government inquiries regarding billing compliance (False Claims Act).
- Non-GAAP Reconciliation: Scrutinize the Adjusted EBITDA reconciliation, particularly the treatment of stock-based compensation and fair value changes in marketable securities.